Canaccord Genuity Maintains Buy on Regulus Therapeutics, Raises Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Whitney Ijem maintains a 'Buy' rating on Regulus Therapeutics (NASDAQ:RGLS) and raises the price target from $9 to $12.
September 21, 2023 | 3:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Canaccord Genuity maintains a 'Buy' rating on Regulus Therapeutics and raises the price target from $9 to $12.
The 'Buy' rating maintained by Canaccord Genuity and the increase in price target from $9 to $12 indicates a positive outlook for Regulus Therapeutics. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100